Navigation Links
Nuvilex, Inc. Announces That Reme-Flu(TM) Will Be Available For Sale On Top-Rated Internet Website
Date:9/15/2009

CHERRY HILL, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), announced today that Legacy Biotechnologies, Inc., its joint venture partner, has informed the Company that Reme-Flu(TM) will soon be available for sale on Nutralegacy.com, one of the top-rated websites in the world. Reme-Flu(TM) is a unique two-part protocol homeopathic remedy designed to help prevent and treat flu-type symptoms resulting from influenza-like illnesses, including swine flu.

Nutralegacy.com is dedicated to providing information to the public on a wide range of health topics, including natural healing, nutrition, skin care, and general health care. The website is updated daily and also features comments from interested readers. According to Alexa, a global and well-known ranking system of websites, Nutralegacy.com is ranked in the top 1/2 of 1 % of all the sites within their ranking system. Alexa uses several sources of data for their ranking algorithm, and it is estimated that they currently keep statistics on and rank 16 million different internet sites. However, according to a 2006 CNN report, there are approximately 100 million active websites in the US alone. This translates to proportionately an even higher ranked status for Nutralegacy.com.

Nutralegacy.com will feature Reme-Flu(TM) on their site and will also publish several new articles on general information regarding the flu viruses, including the swine flu virus (H1N1). Articles on natural and alternative treatments for both preventing the flu and reducing the symptoms and severity of these pervasive viruses may also be found on the site. The vast archive of articles on Nutralegacy.com already has several titles discussing this topic, including "6 Best Natural Remedies for Cold, Flu, and Asthma."

About Legacy Biotechnologies, Inc.

Legacy Biotechnologies, Inc. is an independent, privately owned firm specializing in the research and development of nutraceutical and cosmeceutical formulations. They specialize in creating innovative and cutting-edge compounds that address all facets of health. Its president, Steve Kushner, has been working in this field for over 26 years and has created several original formulas that have been marketed in the United States and abroad. Mr. Kushner's experience allows Legacy Biotechnologies, Inc. to excel at all phases of the health and nutrition industry. In addition to research and development, Legacy Biotechnologies, Inc. is also well versed in the manufacturing process, procurement of raw materials, creation of promotional material, and marketing of products.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink( (R)). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., the Company's ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results
2. Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula
3. Nuvilex, Inc. Finalizes Joint Venture Agreement for the Development of Broad Spectrum All-Natural Flu Remedies
4. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
5. Nuvilex, Inc. Sets Times and Locations for Upcoming Shareholder Meetings
6. Nuvilex, Inc. Announces Business Update Conference Call
7. Nuvilex, Inc. Announces Monthly Investor Conference Call
8. Nuvilex, Inc. Announces Investor Conference Call and Open House
9. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
10. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
11. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: